Talk:Renin inhibitor
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Renin inhibitor.
|
Merge proposal
[edit]I propose merging Discovery and development of renin inhibitors into this article. The development article contains quite a lot of general information about renin inhibitors, and this stub would benefit from that material. --ἀνυπόδητος (talk) 14:22, 14 October 2011 (UTC)
- I agree - it would improve the renin inhbitor article. Adh (talk) 15:01, 29 January 2012 (UTC)
- Done --ἀνυπόδητος (talk) 19:23, 29 January 2012 (UTC)
Copied from Talk:Discovery and development of renin inhibitors
[edit]References needing formatting
[edit]- Brown
- Cumin
- Szelke2
- Gradman
- Novartis
- FDA
--ἀνυπόδητος (talk) 19:52, 28 September 2011 (UTC)
Assessment
[edit]This is a good and rather in-depth overview of the topic, and well sourced. I think it could be structured a bit more systematically, which would make it easier to read – for example, the mechanism of the RAAS and renin is spread out across several sections. I added two tags: one for the image of H-142 which isn't explained (I suppose it's a first-generation renin inhibitor but it needs to say), and one for the last sentence which is borderline promotional with only the manufacturer's website as a source. Calling it "next generation" is a now well-established way to make drugs look better than they are (like levocetirizine which is only the eutomer of the second-generation antihistamine cetirizine but has been labelled "third-generation" by its inventor).
Overall, I'll give this article a C class assessment. Please feel free to ask if you have questions about this. --ἀνυπόδητος (talk) 18:08, 1 October 2011 (UTC)